1naresh
Array ( [urn:ac.highwire.org:guest:identity] => Array ( [runtime-id] => urn:ac.highwire.org:guest:identity [type] => guest [service-id] => ajnr-ac.highwire.org [access-type] => Controlled [privilege] => Array ( [urn:ac.highwire.org:guest:privilege] => Array ( [runtime-id] => urn:ac.highwire.org:guest:privilege [type] => privilege-set [privilege-set] => GUEST ) ) [credentials] => Array ( [method] => guest ) ) ) 1nareshArray ( [urn:ac.highwire.org:guest:identity] => Array ( [runtime-id] => urn:ac.highwire.org:guest:identity [type] => guest [service-id] => ajnr-ac.highwire.org [access-type] => Controlled [privilege] => Array ( [urn:ac.highwire.org:guest:privilege] => Array ( [runtime-id] => urn:ac.highwire.org:guest:privilege [type] => privilege-set [privilege-set] => GUEST ) ) [credentials] => Array ( [method] => guest ) ) )Table 4:Review of emergency treatments of periprocedural thromboembolism
Study No. of Patients Treatment Intracranial Bleeding Events Recanalization Cronqvist et al3 19 IA urokinase 3 (16%) 10 (53%) Fourie and Duncan5 1 IV abciximab 0 (0%) 1 (100%) Ng et al8 1 IV abciximab 0 (0%) 1 (100%) Cloft et al9 4 IV abciximab 0 (0%) 2 (50%) Kwon et al10 3 IA abciximab 0 (0%) 3 (100%) Alexander et al11 1 IV abciximab 0 (0%) 1 (100%) Mounayer et al13 13 IA abciximab 0 (0%) 12 (92%) Bendok et al14 1 IV abciximab 0 (0%) 1 (100%) Song et al15 7 IA abciximab 0 (0%) 5 (71%)
Note:—IA indicates intra-arterial; IV, intravenous.